Cargando…
Targeting EZH2 as a novel therapeutic strategy for sorafenib‐resistant thyroid carcinoma
Thyroid carcinoma is the most common endocrine malignancy. Surgery, post‐operative selective iodine‐131 and thyroid hormone suppression were the most common methods for the therapy of thyroid carcinoma. Although most patients with differentiated thyroid carcinoma (DTC) showed positive response for t...
Autores principales: | Wang, Zhengshi, Dai, Jiaqi, Yan, Jie, Zhang, Yun, Yin, Zhiqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584518/ https://www.ncbi.nlm.nih.gov/pubmed/31087496 http://dx.doi.org/10.1111/jcmm.14365 |
Ejemplares similares
-
Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2022) -
Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
por: Chang, Hang-Seok, et al.
Publicado: (2023) -
EZH2: novel therapeutic target for human cancer
por: Li, Long-Yuan
Publicado: (2014) -
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
por: Kusakabe, Yuko, et al.
Publicado: (2021) -
TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance
por: Xia, Shunjie, et al.
Publicado: (2021)